CytRx drug for soft-tissue sarcomas gets orphan status in Europe The European Commission has granted CytRx's ( CYTR ) Aldoxorubicin therapy orphan medicinal product designation for the treatment of advanced soft-tissue sarcomas, a cancer that occurs in muscle, fat, blood vessels, tendons, fibrous tissues and connective tissue. The classification adds to U.S. orphan designation. Aldoxorubicin is in a Phase III trial of patients whose tumors have progressed ...
March 31, 2014 - Seeking Alpha